A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Stopped Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.

Conditions

• Relapsing Multiple Sclerosis (RMS)

Interventions

• DRUG: Ofatumumab
• BIOLOGICAL: mRNA COVID-19 vaccine
• DRUG: interferon or glatiramer acetate

Sponsor

Novartis Pharmaceuticals